TMTC2 and neoplasm: Ylösmäki and colleagues demonstrated that when adenoviruses are administered directly into tumors after being coated with modified tumor antigen peptides—sourced from proteins such as tyrosinase-related protein 2, human glycoprotein 100, melanoma-associated antigen A1, transmembrane and TPR repeat-containing protein 2, WD repeat domain 11, zinc finger RNA-binding protein, and a disintegrin and metalloproteinase with thrombospondin motifs 9—there is a marked increase in tumor-specific T cell responses.